[ Diabetes Type 2 ]

Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study.

OBJECTIVE With improvements in cardiovascular disease (CVD) rates among people with diabetes, mortality rates may also be changing. Design, Setting, and Participants  A study including all 217 364 individuals younger than 70 years with type 2 diabetes in the Sweden National Diabetes Register (January 1, 2003, to December 31, 2010) who were monitored through December 31, 2012, was conducted. Email: afkarian{at}u.washington.edu Received for publication July 21, 2012. She’s an assistant professor of oncology at the Roswell Park Cancer Institute, in Buffalo, N.Y. Jardiance belongs to a new class of Type 2 diabetes medications known as SGLT2 inhibitors, which lower blood sugar by causing the kidneys to remove sugar from the body through the urine. In particular, this protective association was observed in those with diabetic nephropathy regardless of the daily dose of pioglitazone. The researchers noted the decrease in this group was “in part explained by lower HbA1c levels.

In the EMPA-REG trial, patients with type 2 diabetes and risk factors for heart disease were randomized to receive once-daily doses of either the glucose-lowering drug empagliflozin (10 mg or 25 mg doses), or a placebo. All participants were flagged for mortality surveillance by the England and Wales Office of National Statistics. Lead study investigator Dr. 1. For those at high risk of heart complications — people who’ve already had a heart attack or stroke, have blocked arteries or suffer chronic heart pain — diabetes and heart disease together on average shorten life expectancy by 12 years from age 60, according to a five-decade British study that included about 690,000 people. Given the savings from averting costly hospitalizations, Jardiance should appeal to insurers as well as doctors and patients, even with a wholesale price of $343 per month — among the most expensive for diabetes medicines. During metformin-only treatment, the mortality rate was 25.48 per 1000.

However, it has also been shown that mean blood glucose and A1C show stronger associations with cardiovascular risk factors than does postprandial blood glucose (8). The adjusted hazard ratio was 0.95 (0.64 to 1.40, P = 0.801).

Tags: , ,